Kleemann, Robert

Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate

Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., & Kooistra, T. (2004) · Journal of Biological Chemistry

Peroxisome Proliferator-Activated ReceptorsCytokine Signaling Pathways and Interactions

Cited by 212

Time-Resolved and Tissue-Specific Systems Analysis of the Pathogenesis of Insulin Resistance

Kleemann, R., van Erk, M., Verschuren, L., van den Hoek, A. M., Koek, M., Wielinga, P. Y., Jie, A., Pellis, L., Bobeldijk-Pastorova, I., Kelder, T., et al. (2010) · PLoS ONE

Adipokines, Inflammation, and Metabolic DiseasesDiet, Metabolism, and Disease

Cited by 146

Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin

Salic, K., Morrison, M. C., Verschuren, L., Wielinga, P. Y., Wu, L., Kleemann, R., Gjorstrup, P., & Kooistra, T. (2016) · Atherosclerosis

Fatty Acid Research and HealthAtherosclerosis and Cardiovascular Diseases

Cited by 105

Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice

Arnoldussen, I. A. C., Wiesmann, M., Pelgrim, C. E., Wielemaker, E. M., van Duyvenvoorde, W., Amaral-Santos, P. L., Verschuren, L., Keijser, B. J. F., Heerschap, A., Kleemann, R., et al. (2017) · International Journal of Obesity

Gut microbiota and healthAdipokines, Inflammation, and Metabolic Diseases

Cited by 101

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 65